MarginsXMarginsX
Home › Markets › Health Care › SLXN

Silexion Therapeutics Corp (SLXN)

SLXN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.76
-11.11% on the day
Market cap
$1.1M
Nano cap
Revenue · 2025
$155K
+453.6% on 2024
Net income · 2025
-$11.9M
-7685.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:InterestAndDividendIncomeOperating), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/0001178913-26-000953-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerSLXN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryIsrael
IPO yearNot reported by the screener
SEC CIK0002022416
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inCayman Islands

Financials · 2025

LineValue
Revenue$155K
Net income-$11.9M
Operating income-$11.6M
Net margin-7685.2%
Operating margin-7504.5%
Revenue growth+453.6%
Cash$6.0M
Total assets$7.2M
P/E (computed)Net income was not positive
P/S (computed)7.4×

Warning signs

Cash runway
4.9 months
$4.8M cash at September 30, 2026
Share count, 1 year
+4885.8%
2025-11-09 to 2026-11-12
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
-$31K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Under these circumstances, in accordance with the requirements of Accounting Standards Codification ( ASC ) 205-40, management has concluded that there is substantial doubt about the Company's ability to continue as a going concern, as management believes its current funds will be sufficient to fund its operations for only several months from the date these financial statements are issued."
10-Q 2026-11-12
Cash and burn$4.8M cash; operating cash flow -$2.9M a quarter.Report 2026-09-30
Shares outstanding649,528 (2026-11-12); 3,126,642 a year earlier. 1y figure adjusted for splits (1-for-240 overall).Cover page 2026-11-12
Reverse splits, 3 years3; latest 1-for-24 on 2026-11-11Source 2026-11-11
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-10-28
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-09-25
AuditorKesselman & Kesselman C.P.A.s, Tel-Aviv, IsraelPCAOB Form AP 2026-04-12
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $31K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$18K-$2.5M-$2.1M$4.8MNo debt tags$133K10-Q 2026-11-12
Q2 2026
2026-06-30
$14K-$3.6M-$2.9M$2.2MNo debt tags$154K10-Q 2026-08-14
Q1 2026
2026-03-31
$32K-$2.7M-$3.6M$2.4MNo debt tags$184K10-Q 2026-05-15
Q4 2025
2025-12-31
$69K-$4.4M-$3.0M$6.0MNo debt tags$154K10-K 2026-03-17
Q3 2025
2025-09-30
$39K-$3.3M-$2.8M$9.2MNo debt tags$88K10-Q 2026-11-12
Q2 2025
2025-06-30
$44K-$2.5M-$2.5M$3.5MNo debt tags$49K10-Q 2026-08-14
Q1 2025
2025-03-31
$2K-$1.7M-$2.5M$6.2MNo debt tags$11K10-Q 2026-05-15
Q4 2024
2024-12-31
$3K-$1.7M-$2.9M$1.2MNo debt tags$28K10-K 2026-03-17

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-10-28
Latest annual report10-K/A2026-05-19
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-16
Latest proxyDEFA14A2026-10-19

Source: SEC EDGAR submissions feed, 284 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-43.1%
1 month-53.1%
3 months-82.1%
Year to date-99.6%
1 year-99.7%
From 52-week high-99.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Other listings for this company

TickerNamePrice
SLXNWSilexion Therapeutics Corp Warrant$0.0042

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
SCNIScinai Immunotherapeutics Ltd.$0.4041+1.02%$1.1M
CLDICalidi Biotherapeutics Inc.$0.6023-3.15%$2.2M
VIVSVivoSim Labs Inc.$0.1237-2.68%$2.5M
CELZCreative Medical Technology Holdings Inc.$0.5201-1.51%$4.0M
LIMNLiminatus Pharma Inc.$2.97-0.67%$4.0M
CRISCuris Inc.$0.4358-2.07%$4.1M
BTTCBlack Titan Corporation$0.2873-9.20%$4.3M
AIMAIM ImmunoTech Inc.$0.1310-8.77%$5.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier